ReviewQJM : monthly journal of the Association of Physicians2016
Proton pump inhibitors in IPF: beyond mere suppression of gastric acidity.
Review in QJM : monthly journal of the Association of Physicians, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Pumping Up Dermatologic Drug Reformulation: A Review of How Proton Pump Inhibitors May Revolutionize Scleroderma Treatment.The Journal of clinical and aesthetic dermatology · 2026Review
- The therapeutic effects of vonoprazan against giardiasis in rats: parasitological, pathological, and immunological aspects.Parasitology research · 2025Article
- Commonly prescribed medications and risk of pneumonia and all-cause mortality in people with idiopathic pulmonary fibrosis: a UK population-based cohort study.Pneumonia (Nathan Qld.) · 2025Article
- Esomeprazole inhibits proliferation of scleroderma fibroblasts via cell cycle regulation.Frontiers in pharmacology · 2025Article
- Genome-wide assessment of shared genetic landscape of idiopathic pulmonary fibrosis and its comorbidities.Human genetics · 2024Article
- Radiation-induced gastric injury during radiotherapy: molecular mechanisms and clinical treatment.Journal of radiation research · 2023Review
- Tissue fibrosis induced by radiotherapy: current understanding of the molecular mechanisms, diagnosis and therapeutic advances.Journal of translational medicine · 2023Review
- Combination of esomeprazole and pirfenidone enhances antifibrotic efficacy in vitro and in a mouse model of TGFβ-induced lung fibrosis.Scientific reports · 2022Article
- Effect of anti-reflux therapy on pulmonary function in idiopathic pulmonary fibrosis: a systematic review and meta-analysis.Journal of thoracic disease · 2021Article
- Effect of pantoprazole on I-R-induced myocardial injury in diabetic rats targeting inflammatory cytokine release and oxidative stress.Iranian journal of basic medical sciences · 2021Article
- Paradoxical relationship between proton pump inhibitors and COVID-19: A systematic review and meta-analysis.World journal of clinical cases · 2021Article
- Reply to AlthuwaybiAmerican journal of respiratory and critical care medicine · 2021Article
- Proton Pump Inhibitors in IPF: A Call for Clinical Trials.Frontiers in pharmacology · 2018Review
- Gastroesophageal Reflux and Idiopathic Pulmonary Fibrosis.World journal of surgery · 2017Review
- Response to letter regarding article, 'proton pump inhibitors in IPF: beyond mere suppression of gastric acidity'.QJM : monthly journal of the Association of Physicians · 2017Article
- Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.Respiration; international review of thoracic diseases · 2017Article
- Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model.Frontiers in pharmacology · 2017Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Proton pump inhibitors (PPIs) are structurally composed of benzimidazole core; a pharmacologically common scaffold that makes up nearly one quarter of the hundred most selling drugs including anticancer, opioid, antihistaminic and antihelmintic drugs. In medicinal chemistry, benzimidazoles are coined as privileged scaffolds due to their ability to recognize and bind diverse biological targets. In this regard, PPIs have been linked to other extra-intestinal functions including direct modulation of airway epithelial, vascular endothelial and immune cells. PPIs have been reported to improve outcomes in idiopathic pulmonary fibrosis (IPF) including slowing the decline in measures of lung function, reducing episodes of acute exacerbations and prolonging transplant-free survival. Recently, the evidence-based guidelines for IPF treatment conditionally recommended the use of PPIs in IPF. However, no prospective clinical trial has been conducted to empirically evaluate the safety and efficacy of PPIs in IPF. Here, we discuss emerging anti-inflammatory and antifibrotic activity of PPIs in the context of IPF. We also discuss possible molecular mechanisms by which PPIs may unleash their beneficial effect in IPF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.